Trial Profile

A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CDX-3379 (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Pharmacodynamics
Sponsors Celldex Therapeutics Inc; Kolltan Pharmaceuticals

Most Recent Events

03 Jan 2023 Results of pooled analysis of three studies (NCT00779389, NCT01218048, NCT02473731) assessing response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit, published in the Clinical Cancer Research.
15 Jul 2019 Results published in the Clinical Cancer Research
10 May 2018 Results presented in the Celldex Therapeutics Inc media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com